<DOC>
	<DOCNO>NCT02743637</DOCNO>
	<brief_summary>This Phase 1 dose escalation ass safety , tolerability maximum tolerate dose subcutaneous administer SDX-7320 patient advanced refractory late-stage solid tumor .</brief_summary>
	<brief_title>A Dose Escalation Study SDX-7320 Patients With Advanced Refractory Late-Stage Solid Tumors</brief_title>
	<detailed_description>This Phase 1 dose escalation study assess safety tolerability subcutaneously administer SDX-7320 patient advanced refractory late-stage solid tumor . Once MTD determine 12 patient treat dose level , characterize treatment emergent adverse event ( TEAEs ) .</detailed_description>
	<criteria>Patients least one site radiographically measurable disease . Eastern Cooperative Oncology Group ( ECOG ) status ≤1 . Adequate renal liver function . Life expectancy ≥3 month . Patients undergone organ transplant surgery . The patient known history Hepatitis A , B , C active antiviral therapy . History gastric bypass surgery banding procedure . Uncontrolled refractory hypertension : systolic &gt; 180 diastolic &gt; 110 , hypotension : systolic &lt; 90 diastolic &lt; 50 despite medical treatment . Participation trial investigational agent within 30 day prior enrollment . The rest 12lead electrocardiogram obtain screening show QTc ( Bazett 's correction ) ≥470 ms congenital prolong QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase 1</keyword>
	<keyword>SDX-7320</keyword>
	<keyword>SynDevRx</keyword>
	<keyword>MetAP2</keyword>
	<keyword>Breast</keyword>
	<keyword>Post menopausal</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Endometrial</keyword>
	<keyword>Esophageal</keyword>
	<keyword>Lung</keyword>
	<keyword>Renal</keyword>
	<keyword>Prostate</keyword>
	<keyword>Liver</keyword>
</DOC>